Genome-wide data reveal novel genes for methotrexate response in a large cohort of juvenile idiopathic arthritis cases.

J Cobb, E Cule, H Moncrieffe, A Hinks, S Ursu, F Patrick, L Kassoumeri, E Flynn, M Bulatović, N Wulffraat, B van Zelst, R de Jonge, M Bohm, P Dolezalova, S Hirani, S Newman, P Whitworth, T R Southwood, M De Iorio, L R WedderburnW Thomson

    Research output: Contribution to journalArticlepeer-review

    Abstract

    Clinical response to methotrexate (MTX) treatment for children with juvenile idiopathic arthritis (JIA) displays considerable heterogeneity. Currently, there are no reliable predictors to identify non-responders: earlier identification could lead to a targeted treatment. We genotyped 759 JIA cases from the UK, the Netherlands and Czech Republic. Clinical variables were measured at baseline and 6 months after start of the treatment. In Phase I analysis, samples were analysed for the association with MTX response using ordinal regression of ACR-pedi categories and linear regression of change in clinical variables, and identified 31 genetic regions (P
    Original languageEnglish
    Pages (from-to)356-364
    Number of pages8
    JournalThe pharmacogenomics journal
    Volume14
    Issue number4
    DOIs
    Publication statusPublished - 2014

    Fingerprint

    Dive into the research topics of 'Genome-wide data reveal novel genes for methotrexate response in a large cohort of juvenile idiopathic arthritis cases.'. Together they form a unique fingerprint.

    Cite this